TY - JOUR
T1 - Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC)
T2 - A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice
AU - Ishiguro, Susumu
AU - Yoshimura, Kiyoshi
AU - Tsunedomi, Ryouichi
AU - Oka, Masaaki
AU - Takao, Sonshin
AU - Inui, Makoto
AU - Kawabata, Atsushi
AU - Wall, Terrahn
AU - Magafa, Vassiliki
AU - Cordopatis, Paul
AU - Tzakos, Andreas G.
AU - Tamura, Masaaki
PY - 2015/2/1
Y1 - 2015/2/1
N2 - We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5% of PDAC specimens and 100% of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.
AB - We have recently discovered the potential involvement of angiotensin II type 2 receptor (AT2R) signaling in pancreatic cancer using AT2R deficient mice. To examine the involvement of AT2R expression in human PDAC, expressions of AT2R as well as the major angiotensin II receptor (type 1 receptor, AT1R) in human PDAC and adjacent normal tissue was evaluated by immunohistochemistry and real time PCR using surgically dissected human PDAC specimens. In immunohistochemical analysis, relatively strong AT1R expression was detected consistently in both normal pancreas and PDAC areas, whereas moderate AT2R expression was detected in 78.5% of PDAC specimens and 100% of normal area of the pancreas. AT1R, but not AT2R, mRNA levels were significantly higher in the PDAC area than in the normal pancreas. AT2R mRNA levels showed a negative correlation trend with overall survival. In cell cultures, treatment with a novel AT2R agonist significantly attenuated both murine and human PDAC cell growth with negligible cytotoxicity in normal epithelial cells. In a mouse study, administrations of the AT2R agonist in tumor surrounding connective tissue markedly attenuated growth of only AT2R expressing PAN02 murine PDAC grafts in syngeneic mice. The AT2R agonist treatment induced apoptosis primarily in tumor cells but not in stromal cells. Taken together, our findings offer clinical and preclinical evidence for the involvement of AT2R signaling in PDAC development and pinpoint that the novel AT2R agonist could serve as an effective therapeutic for PDAC treatment.
KW - Angiotensin II type 2 receptor (AT2R)
KW - Apoptosis
KW - Pancreatic ductal adenocarcinoma
KW - Selective AT2R agonist
UR - http://www.scopus.com/inward/record.url?scp=84924533040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924533040&partnerID=8YFLogxK
U2 - 10.1080/15384047.2014.1002357
DO - 10.1080/15384047.2014.1002357
M3 - Article
C2 - 25756513
AN - SCOPUS:84924533040
SN - 1538-4047
VL - 16
SP - 307
EP - 316
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 2
ER -